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   Sir, the immunotherapy is the new modality in medical 
treatment. This kind of treatment has been introduced for 
using in oncology for a few years and the nimotuzumab 
is a new immunotype anticancer drug that is useful for 
management of several cancers[1,2]. Here, the authors 
would like to share experience on using this drug. As a 
immunotype drug, the concern is on the adverse effect 
due to the immunoreaction of the patients. Of overall 6 
cases who used this drug in the experience of the author, 
there is a case with acute reaction after administration 
of nimotuzumab. The case is a male patient with liver 
cancer and the reaction occurred within 10 min after 
receiving of nimotuzumab. The reaction is acute shaking 
and chill. In fact, this kind of reaction can be seen in any 
immunotherapy. Nevertheless, there has been no official 
report on the prevalence of this acute complication of 
nimotuzumab and this report is the first world report on 
this topic. Based on this work, the one-sixth rate seems 
to be very high and should be a concern for the oncologist 
in using this drug. In fact, a recent report from China also 
documented for the high rate of adverse effect in using 
nimotuzumab combining with radiotherapy. In that report, 
it was quoted that “Grade 3-4 adverse events and toxicities 
occurred in 50% of the patients[3].” Nevertheless, this is only 
the preliminary observation and further study to accumulate 
the information is suggested.
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